Literature DB >> 21621131

The ethics of pacemaker deactivation in terminally ill patients.

Michael B Bevins1.   

Abstract

A core principle of American medical ethics holds that an informed and capacitated patient has the right to have treatments withdrawn or withheld. Nevertheless, many clinicians remain reluctant to honor a request to deactivate a patient's pacemaker. This article describes a case in which a patient was denied her request for pacemaker deactivation. Several reasons for this reluctance are discussed, including historical, practical, and ethical considerations for opposing pacemaker deactivation. Ultimately, however, from an ethical standpoint, pacemaker deactivation is similar to withdrawal of other therapies. Fortunately, a recent expert consensus statement supports a patient's right to have her pacemaker deactivated. Pacemaker deactivation should only be performed after robust informed consent, which must include discussion of risks, benefits, and all viable alternatives based on the patient's values and goals.
Copyright © 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21621131     DOI: 10.1016/j.jpainsymman.2011.03.003

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  3 in total

Review 1.  Practical and ethical considerations in the management of pacemaker and implantable cardiac defibrillator devices in terminally ill patients.

Authors:  Mina M Benjamin; Christine A Sorkness
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

Review 2.  Hospice in heart failure: why, when, and what then?

Authors:  Jeffrey L Spiess
Journal:  Heart Fail Rev       Date:  2017-09       Impact factor: 4.214

3.  Features and outcomes of patients who underwent cardiac device deactivation.

Authors:  Lillian C Buchhalter; Abigale L Ottenberg; Tracy L Webster; Keith M Swetz; David L Hayes; Paul S Mueller
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.